Benchmark Reiterates Speculative Buy on Cardio Diagnostics Hldgs, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Cardio Diagnostics Holdings (NASDAQ:CDIO) and maintained a $2 price target.
August 27, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Cardio Diagnostics Holdings and maintained a $2 price target, indicating confidence in the company's potential despite market uncertainties.
The reiteration of a Speculative Buy rating and maintenance of a $2 price target by Benchmark suggests a positive outlook for Cardio Diagnostics Holdings. This could lead to increased investor interest and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100